The purpose of this study is to determine bioequivalence and bioavailability of four different Premarin/MPA test formulations versus the current formulation for Prempro.

Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women

Wyeth

An Open-Label, Single-Dose, Randomized, 4-Period, Partial Crossover Bioequivalence/Bioavailability Study Among Four New Formulations of Premarin 0.45 mg/Medroxyprogesterone Acetate (MPA) 1.5 mg Compared With a Reference Formulation of Premarin/MPA (Prempro) 0.45 mg/1.5 mg in Healthy Postmenopausal Women

Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women

Details and patient eligibility

Trial contacts and locations